AOD-9604: what the research says.
Last updated May 22, 2026
A 16-amino-acid synthetic fragment corresponding to the C-terminus of human growth hormone (residues 177-191), originally developed by an Australian pharmaceutical company as an anti-obesity drug candidate. Designed to retain the lipolytic (fat-mobilizing) properties of HGH while avoiding the anabolic, IGF-1-mediated effects. Here is what the evidence supports, where the trial data plateaued, and what the regulatory boundaries are.
Regulatory notice: AOD-9604 is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. AOD-9604 is not offered by PepScribe. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including AOD-9604. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that AOD-9604’s legal status has changed or that PepScribe will offer it in the future.
What AOD-9604 is.
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide that corresponds to the C-terminal fragment of human growth hormone (HGH residues 177-191), with an additional N-terminal tyrosine added for stability. The lipolytic activity of HGH was mapped to this C-terminal region in early fragment work, and Ng and colleagues at Monash University and Metabolic Pharmaceuticals showed that the isolated 177-191 sequence retained the fat mobilization properties of the full hormone while shedding most of the growth-promoting, IGF-1-mediated activity.
The peptide was developed by Metabolic Pharmaceuticals (Australia) beginning in the late 1990s, with the explicit goal of producing an anti-obesity therapeutic that triggered fat loss without raising IGF-1, stimulating cartilage growth, or altering insulin sensitivity in the way recombinant HGH does. AOD-9604 is, in other words, an attempt to surgically isolate the lipolytic domain of growth hormone from its anabolic and metabolic consequences.
It is important to be precise here: AOD-9604 is not HGH, not a secretagogue, and not a GHRH analog. It does not bind the GH receptor in the canonical signaling way and it does not raise circulating IGF-1 in published human trials. That distinction is the central scientific premise of the molecule.
How it works (proposed mechanisms).
Direct adipocyte stimulation
Preclinical work by Ng et al. (Metabolic Pharmaceuticals, 2000-2002) demonstrated that the HGH 177-191 fragment stimulates lipolysis in isolated rat adipocytes and reduces fat mass in obese rodent models. The peptide appears to act directly on adipose tissue, increasing the breakdown of stored triglycerides and the release of free fatty acids. This is the signature pharmacology that distinguishes it from the broader endocrine effects of full-length HGH.
Receptor interaction (proposed)
Several preclinical studies have proposed that AOD-9604 acts through or in concert with the beta-3 adrenergic receptor pathway, which is the dominant lipolytic and thermogenic receptor on adipocytes. The mechanism is not fully resolved, and AOD-9604 does not appear to be a direct beta-3 agonist in the conventional sense, but the downstream signature (increased cAMP and hormone-sensitive lipase activity) overlaps with beta-3 signaling.
Beyond fat release
Animal studies suggest AOD-9604 may also support fat oxidation, not just release of fatty acids from storage. This matters because lipolysis without oxidation simply reroutes free fatty acids back into storage or other tissues. Whether the fragment retains the full HGH-style fat oxidation profile in humans, however, was one of the open questions the Phase 2 program was designed to answer.
No GH-axis activation
The defining pharmacological feature of AOD-9604 in published human work is the absence of meaningful change in circulating IGF-1, fasting glucose, or insulin sensitivity at the doses studied. Because IGF-1 is the intermediate for most growth hormone effects (cartilage growth, anabolism, insulin resistance), the IGF-1-sparing profile is what made the molecule scientifically interesting as an obesity candidate distinct from recombinant HGH.
Most mechanistic detail comes from the Metabolic Pharmaceuticals development program and a relatively narrow band of academic studies. The molecule has not undergone the volume of independent mechanistic replication that approved drugs typically receive.
What the research suggests.
AOD-9604 reached Phase 2b in human obesity trials before its development program was shelved. The honest summary is that the efficacy data was mixed and did not clearly support advancement to Phase 3.
Phase 2 obesity trials
Heffernan and colleagues, working with Metabolic Pharmaceuticals, ran a series of Phase 2 trials of AOD-9604 in obese adults during the 2000s, including a 12-week dose-ranging study. Earlier signals were promising, with daily oral or subcutaneous dosing producing weight reductions separable from placebo at some dose levels. The larger Phase 2b program that followed, however, did not produce the magnitude or consistency of weight loss that would support a clear path to a registrational Phase 3 obesity trial. Metabolic Pharmaceuticals subsequently shelved the anti-obesity development program.
Metabolic profile
Across the human studies, AOD-9604 did not produce the IGF-1 elevation, fasting glucose changes, or insulin resistance that limit the use of recombinant HGH for fat loss. From a metabolic safety standpoint, this is the strongest reproducible finding in the literature: the fragment behaves pharmacologically distinct from full-length HGH.
Cartilage and osteoarthritis research
After the obesity program plateaued, secondary research interest shifted toward cartilage and osteoarthritis. Preclinical work by Kwon and others reported chondroprotective and cartilage-supportive effects in animal models. This second-generation research is preliminary, has not produced a registered drug, and should not be confused with established treatment for joint disease.
GRAS food-ingredient designation
AOD-9604 received a Generally Recognized as Safe (GRAS) self-affirmed designation for limited food and dietary supplement contexts in the United States. GRAS is a food-ingredient safety determination. It is not a drug approval, it is not a determination of efficacy, and it does not authorize the peptide to be marketed for the treatment of obesity or any medical condition.
Distinction from HGH and GH secretagogues.
It is common to see AOD-9604 described loosely as a "GH peptide" or grouped with secretagogues such as Sermorelin, CJC-1295, or Ipamorelin. That grouping obscures the underlying biology. Recombinant HGH is the full 191-aa hormone. Secretagogues such as Sermorelin act on the pituitary to stimulate the body's own pulsatile GH release, and they raise IGF-1 downstream. AOD-9604 is a 16-aa fragment of HGH that does not stimulate pituitary GH release, does not raise IGF-1 in published human data, and does not act through the same receptor pathway as either HGH or GHRH analogs.
The clinical implication: if a clinician is targeting the GH/IGF-1 axis (for anabolism, sleep architecture, or cartilage anabolism via IGF-1), AOD-9604 is the wrong tool. If the goal is isolated lipolytic activity without GH axis activation, the fragment is at least the right pharmacology in principle. The Phase 2 data is the part that did not deliver to that premise.
Administration (research context).
In the published Metabolic Pharmaceuticals trial program, AOD-9604 was studied via both oral and subcutaneous routes. Oral bioavailability of peptides is generally limited, and the bulk of the human pharmacology literature reflects subcutaneous administration. Trial dosing typically ran in the low-milligram daily range over treatment courses of several weeks to 12 weeks.
No standardized dosing has been established through international regulatory processes, because the peptide is not an approved drug. Compounded use in US clinical settings, where a clinician has determined that a 503A pharmacy may compound it under FDA Category 2/transitional interpretation, follows clinician-defined protocols rather than a registered label.
This is research context, not prescribing guidance. PepScribe does not currently market AOD-9604 as a peptide-direct product, and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations.
Across the Phase 1 and Phase 2 program, AOD-9604 was generally well-tolerated. No major safety signal emerged from the trials, and that is part of why the fragment retains research interest despite the unimpressive Phase 2 efficacy outcome.
Reported side effects
- Mild injection-site reactions (with subcutaneous administration)
- Headache (mild and transient in most reports)
- Occasional gastrointestinal discomfort with oral formulations
Safety profile notes
Published human data did not show clinically meaningful changes in fasting glucose, insulin, or IGF-1 at the doses studied. That pattern separates AOD-9604 from recombinant HGH, which is the comparison point most relevant to its design rationale. The absence of long-term outcome data, the relatively small sample sizes of the trials, and the fact that the molecule never crossed the threshold to a registrational program all mean that its long-term safety in real-world use is not established at the level of an FDA-approved therapeutic.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Legal status.
AOD-9604 is not FDA-approved as a drug. It does not have an obesity indication, an osteoarthritis indication, or any other registered medical use in the United States. The Metabolic Pharmaceuticals development program did not advance the molecule to FDA registration.
In the US food-ingredient context, AOD-9604 received a self-affirmed GRAS designation. GRAS is a separate regulatory pathway intended for food ingredients and dietary supplements. It does not authorize the peptide for medical use, and it should not be interpreted as a stamp of approval for obesity treatment or any therapeutic claim.
For compounding pharmacy purposes, AOD-9604 sits in the FDA Category 2 / transitional bucket alongside other peptides that have not been formally placed on Category 1 but are not clearly prohibited as Category 3. Status may shift as the broader peptide review at FDA and the Pharmacy Compounding Advisory Committee continues through 2026 and into 2027. PepScribe treats this peptide conservatively until status is clarified, which is to say consultation-first and not as a peptide-direct commercial product.
Sermorelin
A growth-hormone-releasing peptide that supports the body's own pulsatile GH release. Different mechanism from AOD-9604, and a different goal: GH axis support rather than isolated lipolysis. Physician-prescribed and delivered to your door.
Get startedSemaglutide
A GLP-1 receptor agonist with a substantial registrational evidence base for weight management, including large Phase 3 trials. Different mechanism, different evidence depth, and currently available through clinician-supervised programs.
Get startedDeep dives
More on AOD-9604.
Research-backed articles covering specific topics in depth.
Talk to a clinician about your goals.
Take the free assessment and a licensed clinician will match you to the right program. Tier 1 peptides are available directly. Transitional fragments such as AOD-9604 are evaluated in consultation, not sold as a commercial product.